ArticleInternational journal of molecular sciences2021
Enzalutamide Enhances PSMA Expression of PSMA-Low Prostate Cancer.
Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 46 citations in OpenAlex.
- 131I-LNTH-1095 Radioligand Therapy plus Enzalutamide versus Enzalutamide Alone in Men with PSMA-Avid Metastatic Castration-Resistant Prostate Cancer: A Phase II Study.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Trial
- Predictive value of early PSMA upregulation for the response to enzalutamide ±Nature cancer · 2026Trial
- Quantitative Analysis of Serial Positron Emission Tomography Imaging in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide.European urology oncology · 2024Trial
- Efficacy and outcomes of [European journal of nuclear medicine and molecular imaging · 2026Article
- Effects of androgen receptor signaling inhibitors on absorbed doses in mCRPC patients undergoing [European journal of nuclear medicine and molecular imaging · 2026Article
- Outcomes of [European journal of nuclear medicine and molecular imaging · 2026Article
- Development and Characterization of the PSMA-Expressing CT26-PSMA Cell Line as a Rapid Preclinical Platform forInternational journal of molecular sciences · 2026Article
- Efficacy, safety, and quality of life outcomes of [International urology and nephrology · 2026Review
- Article
- Novel therapeutic strategies for metastatic castration‑resistant prostate cancer: Beyond androgen receptor pathway inhibition (Review).International journal of oncology · 2026Review
- A 3D co-culture model with fibroblast-restricted FAP expression for cancer therapy using [EJNMMI radiopharmacy and chemistry · 2026Article
- Bimodal Fluorescent Conjugate Based on Prostate-Specific Membrane Antigen Ligands with the Chelating Agent DOTA and SulfoCy5 Dye: Synthesis, Radiolabeling, and Biological Activity.International journal of molecular sciences · 2026Article
- PSMA-Targeting Chimeras for Cell-Type-Specific Degradation of Surface Immune Checkpoint Protein PD-L1.JACS Au · 2026Article
- A novel polyester-drug nanoconjugate with subtype selectivity for high efficacy against PSMA-positive prostate cancer.Regenerative biomaterials · 2026Article
- PSMA expression assessed by [Cancer imaging : the official publication of the International Cancer Imaging Society · 2025Article
- α-Therapy and Combination Strategies to Overcome Resistance and Enhance Clinical Outcomes in Prostate Cancer.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- Development and Evaluation of a Vinyl Sulfone-Based Fluorine-18 Labeling Method for Constructing PSMA-targeted Prostate Cancer Imaging Agents.Molecular imaging and biology · 2025Article
- Enhancing the Half-Life of ODAP-Urea Based Radioligands by Incorporating Albumin-Binding Moieties.Molecular imaging and biology · 2025Article
- Enhancing outcomes in mCRPC: the impact of androgen receptor inhibitor sequencing before 177Lu-PSMA-617 therapy.The oncologist · 2025Article
- Secretome Analysis of Prostate Cancer Cell Lines Reveals Cell Cycle-Dependent PSA Secretion and Potential Biomarkers.Cancers · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 3 countries.
Funding
Abstract
Prostate-specific membrane antigen (PSMA)-directed radioligand therapy (RLT) prolongs overall survival in men with metastatic castration-resistant prostate cancer (mCRPC). However, men with low PSMA expression are excluded from RLT. We explored the effect of androgen receptor blockade with enzalutamide on PSMA expression. Assessment of PSMA and androgen receptor (AR) expression on the human PC cell lines 22Rv1, C4-2, and LNCaP by immunohistochemistry and flow cytometry revealed low (22Rv1) and high (C4-2 and LNCaP) PSMA expression, and high, comparable AR positivity. Treatment with enzalutamide increased PSMA levels in 22Rv1, C4-2, and LNCaP (2.2/2.3/2.6-fold,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.